Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 50, Issue 5, 2009, Pages 994-999

  Nageswara Rao, R ^a   Shinde, Dhananjay D ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

2D LC MS MS; Antiretrovirals; Pharmacokinetics; Rat serum; Restricted access medium (RAM)

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; NEVIRAPINE;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; LINEAR SYSTEM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DIDEOXYNUCLEOSIDES; DRUG MONITORING; EQUIPMENT DESIGN; MODELS, CHEMICAL; NEVIRAPINE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 70349183227     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.07.005     Document Type: Article

References (21)

1. Hobza Zahradńi{dotless}k P., and Weak R. Intermolecular Interactions in Chemistry and Biology (1980), Academia, Prague
2. Yu Z., and Westerlund D. Influence of mobile phase conditions on the clean-up effect of restricted-access media precolumns for plasma samples injected in a column-switching system. Chromatographia 44 (1997) 589-594
3. Boos K.S., and Rudolphi A. The use of restricted-access media in HPLC, part I, classification and review. LC-GC 15 (1997) 602-611
4. Sadilek P., Satinski D., and Solich P. Using restricted-access materials and column switching in high-performance liquid chromatography for direct analysis of biologically-active compounds in complex matrices. Trends Anal. Chem. 26 (2007) 375-384
5. Gisch D.J., Hunter B.T., and Feibush B. Shielded hydrophobic phase: a new concept for direct injection analysis of biological fluids by high-performance liquid chromatography. J. Chromatogr. 433 (1988) 264-268
6. Daluge S.M., Good S.S., Faletto M.B., Miller W.H., Clair M.H.St., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., and Krenitsky T.A. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41 (1997) 1082-1093
7. Hughes W., McDowell J.A., Shenep J., Flynn P., Kline M.W., and Yogev R. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. 43 (1999) 609-615
8. Torres R., LaFon S., Santin M., D'Aquila R., Mulder J., Lancaster D., and Saag M. Abstracts of the 5th Conference on Retrovirals and Opportunistic Infections (1998) p. 203-204, abstract 659
9. Van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo U.G., Westhuizen I.P., Malan D.R., Johnson M.A., Santos B.R., Mulcahy F., Wood R., Levi G.C., Reboredo G., Squires K., Cassetti I., Petit D., Raffi F., Katlama C., Murphy R.L., Horban A., Dam J.P., Hassink E., van Leeuwen R., Robinson P., Wit F.W., and Lange J.M. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
10. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., and Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337 (1997) 734-739
11. Williams G.C., and Sinko P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39 (1999) 211-238
12. Rebiere H., Mazel B., Civade C., and Bonnet P.A. Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. J. Chromatogr. B 850 (2007) 376-383
13. Saux T.L., Chhun S., Rey E., Launay O., Weiss L., Viard J.P., Pons G., and Jullien V. Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. J. Chromatogr. B 865 (2008) 81-90
14. Lewis S.R., White C.A., and Bartlett M.G. Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection. J. Chromatogr. B 850 (2007) 45-52
15. Colombo S., Beguin A., Marzolini C., Telenti A., Biollaz J., and Decosterd L.A. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. J. Chromatogr. B 832 (2006) 138-143
16. Weller D.R., Brundage R.C., Balfour Jr. H.H., and Vezina H.E. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J. Chromatogr. B 848 (2007) 369-373
17. Notari S., Bocedi A., Ippolito G., Narciso P., Pucillo L.P., Tossini G., Donnorso R.P., Gasparrini F., and Ascenzi P. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J. Chromatogr. B 831 (2006) 258-266
18. Aymard G., Legrand M., Trichereau N., and Diquet B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J. Chromatogr. B 744 (2000) 227-240
19. Ravitch J.R., and Moseley C.G. High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid. J. Chromatogr. B 762 (2001) 165-173
20. D'Avolio A., Siccardi M., Sciandra M., Lorena B., Bonora S., Trentini L., and Perri G.D. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B 859 (2007) 234-240
21. Choi S.O., Rezk N.L., and Kashuba A.D.M. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J. Pharm. Biomed. Anal. 43 (2007) 1562-1567